Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2
Sylwia Ammoun(Peninsula College of Medicine and Dentistry), C. Oliver Hanemann(University of Plymouth)
Cited by 54
Related Papers
GATA-4, a potential novel therapeutic target for high-grade meningioma, regulates miR-497, a potential novel circulating biomarker for high-grade meningioma
|EBioMedicine|2020|41
Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target
|EBioMedicine|2017|30
Human Endogenous Retrovirus Type K Promotes Proliferation and Confers Sensitivity to Antiretroviral Drugs in Merlin-Negative Schwannoma and Meningioma
|Cancer Research|2021|25
A novel patient-derived meningioma spheroid model as a tool to study and treat epithelial-to-mesenchymal transition (EMT) in meningiomas
|Acta Neuropathologica Communications|2023|15